Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
36 Items
Title  Creator  Group name  Publishing year 
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study Adenis et al. EquipeMY 2024-09
Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study Nicolle et al. EquipeAD 2024-10-08
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol Rouanet et al. EquipeMY 2023-10
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database Courtinard et al. EquipeCTCS 2023-03-08
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors Bordeau et al. EquipeMY 2023-09-20
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study Michalet et al. EquipeMY 2022
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database Bini et al. EquipeADV 2022-08-26 00:00:00
Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study Michalet et al. EquipeJPP 2022-04-12
Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management Quesada et al. EquipeJPP 2022
Different meaning of the mean heart dose between 3D-CRT and IMRT for breast cancer radiotherapy Prunaretty et al. EquipeJPP 2022
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) Deshayes et al. EquipeJPP 2022-12-22
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ Bourgier et al. EquipeJPP 2021-11
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results Bascoul-Mollevi et al. EquipeCTCS 2021-01
Prognostic Value of CXCR2 in Breast Cancer Boissière-Michot et al. EquipeCTCS 2020-07-27
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure de Meric de Bellefon et al. EquipeJPP 2020-03
Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes Frere et al. EquipeAD 2020-04
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative Cohen et al. EquipeMY 05/2020
Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial Jacot et al. EquipePC 2020-10-09
Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial Carayol et al. EquipeCTCS Jul 25, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program Jacot et al. EquipeCTCS May 14, 2019
Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity Lacombe et al. EquipePC Aug 09, 2019
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma Sgarbura et al. EquipeCG Jun 01, 2019
Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial Boige et al. EquipeMY May 20, 2019
[Impacts of routine patient-reported-outcomes monitoring in oncology] Fiteni et al. EquipeCG Jul 19, 2018
12>>>
36 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés